Table 2.
Summary of adverse events in randomized controlled trials included in the meta-analysis
| Outcome | Studies | Fibrin sealant events/total | Control events/total | Heterogeneity ( P, I 2 ) | Statistical method | Effect estimate | P value |
|---|---|---|---|---|---|---|---|
| Any adverse events |
3 |
61/164 |
50/164 |
0.007, 80% |
Risk ratio (M-H, fixed, 95% CI) |
1.21 (0.63, 2.31) |
0.57 |
| Fever |
3 |
34/164 |
32/164 |
0.94, 0% |
Risk ratio (M-H, fixed, 95% CI) |
1.06 (0.79, 1.44) |
0.69 |
| Infection |
2 |
3/129 |
2/129 |
0.71, 0% |
Risk ratio (M-H, fixed, 95% CI) |
1.50 (0.26, 8.72) |
0.65 |
| Hematoma | 2 | 3/60 | 10/63 | 0.90, 0% | Risk ratio (M-H, fixed, 95% CI) | 0.31 (0.09, 1.08) | 0.07 |
M-H Mantel-Haenszel.